About Exosiris
Exosiris is pioneering the next generation of nanomedicine through advanced extracellular vesicle platforms designed for targeted therapeutic delivery. Our mission is to transform the way complex diseases are treated by providing safe, precise, and scalable solutions. By harnessing the unique properties of this technology we aim to unlock innovative treatments in oncology, regenerative medicine, and autoimmune disorders, areas where current therapies often fall short.
At Exosiris, we are committed not only to scientific excellence but also to making advanced therapies accessible worldwide, bridging the gap between cutting-edge research and real patient needs.making advanced therapies accessible worldwide.
Democratization of therapies for unmet clinical needs, transforming healthcare together
Pioneering a new generation of nanomedicine for precise and minimally invasive therapeutic delivery
Maria Loustau, Ph.D. – CSO
Biotech leader with 15+ years in biotech R&D and strategic management. Developer of first-in-class anti-HLA-G CAR-T cells and a pioneer in antibodies, nanobodies, and checkpoint targets. Co-inventor on seven patents, recipient of CPRIT funding, and twice recognized by MATWIN for innovation. Brings deep expertise in next-generation therapy development, leading multidisciplinary teams and translational partnerships with a strong strategic vision. Committed to scientific excellence and focused on translating breakthroughs into impactful patient therapies.
Leadership Team
Julien Caumartin, Ph.D. – CEO
IImmunologist with nearly 20 years advancing the understanding of the tumor microenvironment and tumor–immune evasion. Co-developer of the first anti-HLA-G CAR-T cells (in clinical trial at MD Anderson) and a driver of novel CAR strategies against complex tumor antigens. Renowned for bridging fundamental immunology and translational innovation, he leads next-generation therapy development in pharma, with deep expertise in immune checkpoint pathways and a strong track record in scientific leadership, strategic direction, and partnerships.
Scientific Co-Founders & Advisors
